European Journal of Case Reports in Internal Medicine (Mar 2022)

Can Lenalidomide Protect against Severe COVID-19 Symptoms in Multiple Myeloma Patients? A Case Series and Review of the Literature

  • Ali Al Sbihi,
  • Nouraldeen Manasrah,
  • Dahlia Sano

DOI
https://doi.org/10.12890/2022_003216

Abstract

Read online

We present a case series of three multiple myeloma (MM) patients on lenalidomide for maintenance therapy who were at high risk of coronavirus disease 2019 (COVID-19) complications and mortality. However, our patients had minor symptoms after testing positive for COVID-19 although they were unvaccinated. We think that lenalidomide might have a protective effect against severe COVID-19 symptoms.

Keywords